Mesna
Ifex, Ifex/mesnex, Ifosfamide/mesna, Mesna, Mesnex (mesna) is a small molecule pharmaceutical. Mesna was first approved as Ifex on 1988-12-30. It is used to treat cystitis and hemorrhage in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Mesna, Mesnex (discontinued: Mesna)
CombinationsIfex/mesnex (discontinued: Ifex/mesnex, Ifosfamide/mesna)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ifosfamide
+
Mesna
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ifex | New Drug Application | 2024-06-20 |
| mesna | ANDA | 2024-10-15 |
| mesna mesnex | 2006-05-16 | |
| mesnex | New Drug Application | 2024-07-22 |
Indications
FDA
EMA
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05C: Expectorants, excl. combinations with cough suppressants
— R05CB: Mucolytics
— R05CB05: Mesna
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AF: Detoxifying agents for antineoplastic treatment
— V03AF01: Mesna
HCPCS
Code | Description |
|---|---|
| J9209 | Injection, mesna, 200 mg |
Clinical
Clinical Trials
752 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 55 | 147 | 35 | 8 | 12 | 230 |
| Sarcoma | D012509 | — | — | 23 | 71 | 36 | 3 | 18 | 139 |
| Leukemia | D007938 | — | C95 | 32 | 58 | 17 | 3 | 6 | 102 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 23 | 56 | 17 | 3 | 4 | 85 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 16 | 36 | 17 | 5 | 3 | 68 |
| B-cell lymphoma | D016393 | — | — | 20 | 38 | 8 | 1 | 3 | 59 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 18 | 36 | 5 | 1 | 3 | 55 |
| Lymphoid leukemia | D007945 | — | C91 | 12 | 27 | 13 | 4 | 1 | 50 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 9 | 30 | 7 | 2 | 3 | 43 |
| T-cell lymphoma | D016399 | — | — | 6 | 19 | 2 | 4 | — | 29 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 41 | 41 | 9 | — | 5 | 79 |
| Osteosarcoma | D012516 | — | — | 12 | 25 | 8 | — | 7 | 45 |
| Hodgkin disease | D006689 | — | C81 | 13 | 27 | 9 | — | 4 | 43 |
| Recurrence | D012008 | — | — | 12 | 19 | 3 | — | 1 | 29 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 10 | 13 | 4 | — | 3 | 28 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 10 | 19 | 5 | — | — | 27 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 4 | 11 | 6 | — | 5 | 25 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 20 | 2 | — | — | 24 |
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 16 | 1 | — | 2 | 24 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 10 | 14 | 1 | — | 1 | 23 |
Show 89 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 12 | 18 | — | — | 1 | 23 |
| Melanoma | D008545 | — | — | 9 | 15 | — | — | 1 | 22 |
| Syndrome | D013577 | — | — | 4 | 11 | — | — | 1 | 12 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 10 | — | — | — | 11 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 10 | — | — | — | 10 |
| Mantle-cell lymphoma | D020522 | — | — | 4 | 8 | — | — | — | 9 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 3 | 7 | — | — | — | 8 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 2 | 7 | — | — | — | 8 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 7 | — | — | — | 8 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 7 | — | — | — | 7 |
Show 156 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | 1 | 2 |
| Ganglioneuroblastoma | D018305 | — | — | 1 | — | — | — | — | 1 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | 1 | — | — | — | — | 1 |
| Thymoma | D013945 | — | — | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
| Vasculitis | D014657 | HP_0002633 | — | 1 | — | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | 1 | — | — | — | — | 1 |
| Muscular diseases | D009135 | HP_0003198 | G72.9 | 1 | — | — | — | — | 1 |
| Neuroepithelial neoplasms | D018302 | — | — | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobinopathies | D006453 | — | D58.2 | — | — | — | — | 2 | 2 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | — | 2 | 2 |
| Histiocytosis | D015614 | HP_0100727 | — | — | — | — | — | 1 | 1 |
| Langerhans-cell histiocytosis | D006646 | — | C96.6 | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | — | — | — | 1 | 1 |
| Severe combined immunodeficiency | D016511 | HP_0004430 | D81.6 | — | — | — | — | 1 | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | — | 1 | 1 |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 1 | 1 |
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | — | — | 1 | 1 |
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mesna |
| INN | mesna |
| Description | Mesna, sold under the brand name Mesnex among others, is a medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder. It is used either by mouth or injection into a vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=S(=O)([O-])CCS.[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 19767-45-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL975 |
| ChEBI ID | — |
| PubChem CID | 29769 |
| DrugBank | — |
| UNII ID | NR7O1405Q9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,281 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ifex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,538 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use